Potential for micro-RNA based cancer treatments
18 Jul 2012
Potential for micro-RNA based cancer treatments
Bevacizumab benefits beyond progression in TML study subgroups
Translational and tailored, but can we afford it?
Translational and tailored, but can we afford it?
Cost efficiency of targeted therapy
Translating cancer research to personalised treatment: Can it work?
The immuno side of melanoma
Constructing successful biomarker clinical trials
Highlights of the 22nd EACR meeting and tackling glioblastoma
The changing field of drug development
Epigenetics of cancer and changes in DNA modification in tumours
Adjuvant cetuximab disappoints again in mCRC